ES2123642T3 - Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m. - Google Patents

Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.

Info

Publication number
ES2123642T3
ES2123642T3 ES93907581T ES93907581T ES2123642T3 ES 2123642 T3 ES2123642 T3 ES 2123642T3 ES 93907581 T ES93907581 T ES 93907581T ES 93907581 T ES93907581 T ES 93907581T ES 2123642 T3 ES2123642 T3 ES 2123642T3
Authority
ES
Spain
Prior art keywords
phase
halometilideno
cancer
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907581T
Other languages
English (en)
Inventor
Sai P Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2123642T3 publication Critical patent/ES2123642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UN ESTADO DE ENFERMEDAD NEOPLASTICA Y QUE CONSISTE EN ADMINISTRAR A DICHO PACIENTE UNA CANTIDAD ANTINEOPLASTICA EFECTIVA DE UN DERIVADO DE 2''-HALOMETILIDENO JUNTO CON UNA TERAPIA CON UNA CANTIDAD ANTINEOPLASTICA EFECTIVA DE UN AGENTE ESPECIFICO DE S-FASE O M-FASE.
ES93907581T 1992-04-10 1993-03-15 Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m. Expired - Lifetime ES2123642T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10

Publications (1)

Publication Number Publication Date
ES2123642T3 true ES2123642T3 (es) 1999-01-16

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907581T Expired - Lifetime ES2123642T3 (es) 1992-04-10 1993-03-15 Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.

Country Status (17)

Country Link
US (2) US20040102461A1 (es)
EP (1) EP0664708B1 (es)
JP (1) JP3713668B2 (es)
KR (1) KR100258668B1 (es)
AT (1) ATE170077T1 (es)
AU (1) AU667527B2 (es)
CA (1) CA2117891C (es)
DE (1) DE69320646T2 (es)
DK (1) DK0664708T3 (es)
ES (1) ES2123642T3 (es)
HU (1) HU219476B (es)
IL (1) IL105329A (es)
MX (1) MX9302038A (es)
NZ (1) NZ251211A (es)
TW (1) TW362971B (es)
WO (1) WO1993020825A1 (es)
ZA (1) ZA932455B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
WO1996001834A1 (fr) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
CA2302754C (en) 1997-09-04 2011-11-08 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
CA2326004A1 (en) 2000-11-02 2002-05-02 Richard E. Jones Methods for treating cellular proliferative disorders
CA2476279A1 (en) * 2002-02-14 2003-08-21 Lieven J. Stuyver Modified fluorinated nucleoside analogues
WO2004042081A1 (de) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
BR112014014740B1 (pt) 2011-12-22 2021-08-24 Alios Biopharma, Inc Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Also Published As

Publication number Publication date
MX9302038A (es) 1993-10-01
EP0664708B1 (en) 1998-08-26
JPH07505653A (ja) 1995-06-22
HU9402914D0 (en) 1995-01-30
US20040102461A1 (en) 2004-05-27
DE69320646D1 (de) 1998-10-01
AU667527B2 (en) 1996-03-28
TW362971B (en) 1999-07-01
JP3713668B2 (ja) 2005-11-09
HU219476B (hu) 2001-04-28
WO1993020825A1 (en) 1993-10-28
CA2117891C (en) 1998-07-07
EP0664708A1 (en) 1995-08-02
AU3813193A (en) 1993-11-18
ATE170077T1 (de) 1998-09-15
US20050032738A1 (en) 2005-02-10
IL105329A0 (en) 1993-08-18
KR950700749A (ko) 1995-02-20
IL105329A (en) 1998-06-15
DK0664708T3 (da) 1998-11-02
DE69320646T2 (de) 1999-01-14
ZA932455B (en) 1993-10-20
NZ251211A (en) 1997-05-26
EP0664708A4 (en) 1995-04-24
HUT71224A (en) 1995-11-28
CA2117891A1 (en) 1993-10-28
KR100258668B1 (ko) 2000-07-01

Similar Documents

Publication Publication Date Title
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
DE69521994D1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
SE9301951D0 (sv) Methods for administration of taxol
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
PT933995E (pt) Metodo para tratamento de lesao endotelial
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
SE9000207D0 (sv) Laekemedel samt anvaendningen av detsamma
GR3022608T3 (en) USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE.
BR9708037A (pt) Método para o tratamento de abuso de substância
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
BR9713828A (pt) Tratamento de tumores altamente vasculares
RU94037731A (ru) Способ лечения рассеянного склероза
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664708

Country of ref document: ES